Bioxcel therapeutics announces completion of patient enrollment in safety portion of investigator-sponsored phase 2 relapsed pancreatic cancer trial of bxcl701 in combination with keytruda®

Human proof of concept portion of the trial expected to begin in h1 2024; led by georgetown lombardi comprehensive cancer center

BTAI Ratings Summary

BTAI Quant Ranking